Public spending on orphan medicines: a review of the literature

References

• Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Brussels; 2000. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32000R0141.
   Google Scholar
• Hsu JC, Wu H-C, Feng W-C, Chou C-H, Lai EC-C, Lu CY. Disease and economic burden for rare diseases in Taiwan: a longitudinal study using Taiwan’s National Health Insurance Research Database. PLoS One. 2018;13(9):e0204206.
   PubMed Web of Science ®Google Scholar
• Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, et al. Rare disease terminology and definitions—a systematic global review: report of the ISPOR Rare Disease Special Interest Group. Value Health. 2015;18(6):906–914.
   PubMed Web of Science ®Google Scholar
• Gammie T, Lu CY, Babar ZU-D. Access to orphan drugs: a comprehensive review of legislations, regulations and policies in 35 countries. PLoS One. 2015;10(10):e0140002.
   PubMed Web of Science ®Google Scholar
• Cote A, Keating B. What is wrong with orphan drug policies? Value Health. 2012;15(8):1185–1191.
   PubMed Web of Science ®Google Scholar
• Kanavos P, Nicod E. What is wrong with orphan drug policies? Suggestions for ways forward. Value Health. 2012;15(8):1182–1184.
   PubMed Web of Science ®Google Scholar
• Picavet E, Dooms M, Cassiman D, Simoens S. Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy. 2011;9(4):275–279.
   PubMedGoogle Scholar
• Castaneda-Sanabria J, Hajage D, Le Jouan M, Perozziello A, Tubach F. Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field. Eur J Clin Pharmacol. 2016;72(6):737–746.
   PubMed Web of Science ®Google Scholar
• Picavet E, Morel T, Cassiman D, Simoens S. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis. 2014;9:62.
   PubMed Web of Science ®Google Scholar
• Young KE, Soussi I, Toumi M. The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change. J Mark Access Health Policy. 2017;5(1):1369817.
   PubMedGoogle Scholar
• Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.
   PubMed Web of Science ®Google Scholar
• Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoecon Outcomes Res. 2012;12(1):23–29.
   PubMed Web of Science ®Google Scholar
• Szegedi M, Zelei T, Arickx F, Bucsics A, Cohn-Zanchetta E, Furst J, et al. The European challenges of funding orphan medicinal products. Orphanet J Rare Dis. 2018;13:184.
   PubMed Web of Science ®Google Scholar
• Malinowski KP, Kawalec P, Trabka W, Czech M, Petrova G, Manova M, et al. Reimbursement legislations and decision making for orphan drugs in Central and Eastern European countries. Front Pharmacol. 2019;10:487.
   PubMed Web of Science ®Google Scholar
• Kamusheva M, Stoimenova A, Doneva M, Zlatareva A, Petrova G. A cross-country comparison of reimbursed orphan medicines in Bulgaria, Greece and Romania. Biotechnol Biotechnol Equip. 2013;27(5):4186–4192.
   Web of Science ®Google Scholar
• Malinowski KP, Kawalec P, Trabka W, Sowada C, Pilc A. Reimbursement of orphan drugs in Europe in relation to the type of authorization by the European Medicines Agency and the decision making based on health technology assessment. Front Pharmacol. 2018;9:1263.
   PubMed Web of Science ®Google Scholar
• Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. Appl Health Econ Health Policy. 2017;15(3):307–321.
   PubMed Web of Science ®Google Scholar
• OECD. New health technologies: managing access, value and sustainability. Paris: OECD Publishing; 2017.
   Google Scholar
• Vogler S, Paris V, Panteli D. Ensuring access to medicines: how to redesign pricing, reimbursement and procurement? European Observatory on Health Care Systems. Copenhagen: WHO Regional Office for Europe; 2018
   Google Scholar
• Morel T, Arickx F, Befrits G, Siviero P, van der Meijden C, Xoxi E, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis. 2013;8:198.
   PubMed Web of Science ®Google Scholar
• Morel T, Arickx F, Befrits G, Siviero PD, van der Meijden CMJ, Xoxi E, et al. Managed entry agreements and orphan drugs: a European comparative study (2006-2012). Value Health. 2013;16(7):A391.
   Web of Science ®Google Scholar
• Denis A, Mergaert L, Fostier C, Cleemput I, Simoens S. Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ. 2010;13(2):295–301
   PubMedGoogle Scholar
• Kanters TA, Steenhoek A, Hakkaart L. Orphan drugs expenditure in the Netherlands in the period 2006-2012. Orphanet J Rare Dis. 2014;9:154.
   PubMed Web of Science ®Google Scholar
• Graf von der Schulenburg JM, Frank M. Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems. Eur J Health Econ. 2015;16(2):113–118.
   PubMed Web of Science ®Google Scholar
• Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020. Orphanet J Rare Dis. 2011;6:62.
   PubMed Web of Science ®Google Scholar
• Schlander M, Adarkwah CC, Gandjour A. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(1):171–179
   PubMed Web of Science ®Google Scholar
• Orofino J, Soto J, Casado MA, Oyaguez I. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007. Appl Health Econ Health Policy. 2010;8(5):301–315
   PubMedGoogle Scholar
• Hutchings A, Schey C, Dutton R, Achana F, Antonov K. Estimating the budget impact of orphan drugs in Sweden and France 2013–2020. Orphanet J Rare Dis. 2014;9(1):22.
   PubMedGoogle Scholar
• Iskrov G, Jessop E, Miteva-Katrandzhieva T, Stefanov R. Budget impact of rare diseases: proposal for a theoretical framework based on evidence from Bulgaria. Georgian Med News. 2015;5(242):46–53
   Google Scholar
• Iskrov GG, Jakovljevic MM, Stefanov RS. Budgetary impact of medicinal therapies for rare diseases in Bulgaria. Folia Med. 2018;60(1):79–91
   Google Scholar
• Logviss K, Krievins D, Purvina S. Impact of orphan drugs on Latvian budget. Orphanet J Rare Dis. 2016;11:59.
   PubMed Web of Science ®Google Scholar
• Divino V, DeKoven M, Kleinrock M, Wade R, Kaura S. Orphan drug expenditures in the United States: a historical and prospective analysis, 2007-18. Health Aff. 2016;35(9):1588–1594.
   PubMed Web of Science ®Google Scholar
• Divino V, DeKoven M, Kleinrock M, Wade RL, Kim T, Kaura S. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis. Orphanet J Rare Dis. 2016;11:68.
   PubMed Web of Science ®Google Scholar
• Kockaya G, Wertheimer AI, Kilic P, Tanyeri P, Mert Vural I, Akbulat A, et al. An overview of the orphan medicines market in Turkey. Value Health Reg Issues. 2014;4C:47–52.
   Google Scholar
• Deticek A, Locatelli I, Kos M. Patient access to medicines for rare diseases in European countries. Value Health. 2018;21:553–560
   PubMed Web of Science ®Google Scholar
• OECD. Health at a glance 2015: OECD indicators. Paris: OECD Publishing; 2015.
   Google Scholar
• The Council of the European Union. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States. 2016.
   Google Scholar
• Vogler S, Paris V, Pantelli D. Policy Brief 30: ensuring access to medicines: How to redesign pricing, reimbursement and procurement? European Observatory. 2018
   Google Scholar
• OECD. Pharmaceutical innovation and access to medicines. Paris: OECD Publishing; 2018.
   Google Scholar
• Singapore Statutes Online. Medicines Act (Chapter 176,Section 9) Medicines (Orphan Drugs), (Exemption) Order,G.N. No. S 470/1991, Revised Edition; 2005. https://sso.agc.gov.sg/SL/MA1975-OR12?DocDate=20050331&ValidDate=20160122&TransactionDate=20160122. Accessed 24 Aug 2020.
   Google Scholar
• Therapeutic goods regulations (Amendment), 399 (1997). https://www.legislation.gov.au/Details/F1997B02888.
   Google Scholar
• Health Promotion Administration. The Rare Disease and Orphan Drug Act. 2000Available from: https://www.hpa.gov.tw/EngPages/Detail.aspx?nodeid=1058&pid=6031. Accessed 31 May 2019
   Google Scholar
• Yousefi-Nooraie R, Shakiba B, Mortaz-Hejri S. Country development and manuscript selection bias: a review of published studies. BMC Med Res Methodol. 2006;6:37.
   PubMedGoogle Scholar
• Harris M, Macinko J, Jimenez G, Mullachery P. Measuring the bias against low-income country research: an implicit association test. Global Health. 2017;13:80.
   PubMed Web of Science ®Google Scholar
• Smith E, Hunt M, Master Z. Authorship ethics in global health research partnerships between researchers from low or middle income countries and high income countries. BMC Med Ethics. 2014;15:42.
   PubMed Web of Science ®Google Scholar
• OECD, Eurostat, and World Health Organization. A system of health accounts 2011: revised edition. Paris: OECD Publishing; 2017.
   Google Scholar
• Pavlović N, Stanimirov B, Stojančević M, Paut-Kusturica M, Stoimenova A, Goločorbin-Kon S, et al. An insight on differences in availability and reimbursement of orphan medicines among Serbia, Bulgaria and Sweden. Biotechnol Biotechnol Equip. 2012;26(5):3236–3241.
   Web of Science ®Google Scholar
• Sarnola K, Ahonen R, Martikainen JE, Timonen J. Policies and availability of orphan medicines in outpatient care in 24 European countries. Eur J Clin Pharmacol. 2018;74(7):895–902
   PubMed Web of Science ®Google Scholar
• Zamora B, Garau M, Maignen F, O’Neill P, Mestre-Ferrandiz J. OP138 access to orphan drugs in the United Kingdom and other European countries. Towards an HTA ecosystem: from local needs to global opportunities; 2017.
   Google Scholar